Retention of bacteriophages (Φ6, PR772, T1, and PP7) and mammalian viruses (poliovirus
and influenza A virus) by a hydrophilic triple layer PVDF microporous membrane, the Ultipor …

Viral agents (influenza A virus, 80—120 nm; phage T1, 50 nm head, 150 nm head, 150 nm
tail; phage PR772, 53 nm; poliovirus, 28—30 nm; and phage PP7, 25 nm) were used to …

Continuous cell lines (used in the manufacture of monoclonal antibodies and other
therapeutic proteins) may harbour retroviral particles; nevertheless, they are deemed …

The efficiency of sequential incorporation of two approaches to virus removal, ie, tangential
flow ultrafiltration using the Omega™ 300K VR Maximate™ System, and, direct flow …

Preventing viral contamination is critical in the manufacturing of safe and effective
biotherapeutic proteins. Virus filtration is an integral part of the overall strategy for viral …

Incorporation of adequate clearance methodologies for viral safety assurance constitutes an
integral part of the manufacturing process for plasma-derived biologicals. Filtration, being …

Virus removal by a novel filter (Ultipor VF DV50), comprising three layers of PVDF
membrane, has been evaluated by infectivity studies using a range of viruses and …

Virus filtration with nanometer size exclusion membranes (“nanofiltration”) is effective for
removing infectious agents from biopharmaceuticals. While the virus removal capability of …

Virus filtration can provide a robust, size-based viral clearance mechanism in the production
of biotherapeutics. Successful application of virus filtration requires membranes with both …

Membranes are used in most processes of biopharmaceutical production. It is used for
pretreatment of other processes, separation of impurities in the process, virus removal …